EntreMed Executive Summary 1.1 History and Background EntreMed, Inc., Maryland founded in 1991 and publicly-traded since 1996 (NASDAQ: ENMD) a clinical-stage biopharmaceutical company developing therapeutics that "act on multiple cellular pathways involved in processes such as abnormal blood vessel growth, inflammation, coagulation, and programmed cell death"(entremed.com) Through a combination of both foresight and fortuity, EntreMed, in 1993, initiated its collaboration with Dr. Judah Folkman, the father of angiogenesis, who, more than 30 years ago, discovered that tumors were …
showed first 75 words of 3247 total

showed last 75 words of 3247 total
…Challener, C. (2003, February 24). Market reactions: Custom players offer their views from the trenches. Chemical Market Reporter. 8, FR3 Biotechnology - A Consistent Record of Growth, Biotechnology Industry Organization, www.bio.org Finding Funding - Opportunities and Caveats, About, Inc www.biotechabout.com Krause, C. (2003, March 17). Fewer financing opportunities in biotechnology sector has altered deal-making strategies. Chemical Market Reporter. 11, 12 Manufacturing, Human Genome Sciences, www.hgsi.com Scott, A. (2003, September 24). Biopharma manufacturing capacity comes into balance. Chemical Week. 33, 58